Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Proposal To Expand Aprepitant Coverage Could Also Benefit Tesaro’s Rolapitant

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS’ proposed update to its Medicare Part B National Coverage Determination would provide payment for aprepitant when used for patients receiving moderately emetogenic chemotherapy, not just highly emetogenic treatments.

You may also be interested in...

Flush With Cash, Tesaro Advances Rolapitant Toward NDA

Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.

Genetic Testing, But No Drugs, On Revised List Of Potential Medicare NCD Topics

CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.

CMS Reviewing Aprepitant NCD To Add Use With Moderately Emetogenic Chemo

The current Medicare Part B national coverage determination says use of the anti-nausea drug with highly emetogenic anti-cancer chemotherapy is reasonable and necessary; the National Comprehensive Cancer Network asks CMS to update the NCD based on evidence supporting use with moderately emetogenic agents.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts